ReviewInternational journal of nanomedicine2020
Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies.
Review in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Nanodrugs for the Treatment of Ischemic Stroke: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.Materials today. Bio · 2025Review
- Nanoparticles for Thrombolytic Therapy in Ischemic Stroke: A Systematic Review and Meta-Analysis of Preclinical Studies.Pharmaceutics · 2025Review
- The Role of Extracellular Vesicles and Microparticles in Central Nervous System Disorders: Mechanisms, Biomarkers, and Therapeutic Potential.Cellular and molecular neurobiology · 2024Review
- Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke.Journal of nanobiotechnology · 2024Article
- Innovations in Breaking Barriers: Liposomes as Near-Perfect Drug Carriers in Ischemic Stroke Therapy.International journal of nanomedicine · 2024Review
- Extracellular vesicles and their microRNA cargo in ischaemic stroke.The Journal of physiology · 2023Article
- Theranostics Nanomedicine Applications for Colorectal Cancer and Metastasis: Recent Advances.International journal of molecular sciences · 2023Review
- Nanotechnology in Stroke: New Trails with Smaller Scales.Biomedicines · 2023Review
- Application of stimuli-responsive nanomedicines for the treatment of ischemic stroke.Frontiers in bioengineering and biotechnology · 2023Review
- Nanoparticle and Stem Cell Combination Therapy for the Management of Stroke.Current pharmaceutical design · 2023Article
- Cell membrane-camouflaged PLGA biomimetic system for diverse biomedical application.Drug delivery · 2022Article
- New Strategies for Stroke Therapy: Nanoencapsulated Neuroglobin.Pharmaceutics · 2022Review
- Mechanisms of chemotherapeutic resistance and the application of targeted nanoparticles for enhanced chemotherapy in colorectal cancer.Journal of nanobiotechnology · 2022Review
- Oxidative Stress in Ischemia/Reperfusion Injuries following Acute Ischemic Stroke.Biomedicines · 2022Review
- Editorial: Advances and challenges in stroke therapy: A regenerative prospective.Frontiers in neuroscience · 2022Article
- Dodging blood brain barrier with "nano" warriors: Novel strategy against ischemic stroke.Theranostics · 2022Review
- Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke.Life (Basel, Switzerland) · 2021Review
- The Role of Natural Compounds and their Nanocarriers in the Treatment of CNS Inflammation.Biomolecules · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The technology of drug delivery systems (DDS) has expanded into many applications, such as for treating neurological disorders. Nanoparticle DDS offer a unique strategy for targeted transport and improved outcomes of therapeutics. Stroke is likely to benefit from the emergence of this technology though clinical breakthroughs are yet to manifest. This review explores the recent advances in this field and provides insight on the trends, prospects and challenges of translating this technology to clinical application. Carriers of diverse material compositions are presented, with special focus on the surface properties and emphasis on the similarities and inconsistencies among in vivo experimental paradigms. Research attention is scattered among various nanoparticle DDS and various routes of drug administration, which expresses the lack of consistency among studies. Analysis of current literature reveals lipid- and polymer-based DDS as forerunners of DDS for stroke; however, cell membrane-derived vesicles (CMVs) possess the competitive edge due to their innate biocompatibility and superior efficacy. Conversely, inorganic and carbon-based DDS offer different functionalities as well as varied capacity for loading but suffer mainly from poor safety and general lack of investigation in this area. This review supports the existing literature by systematizing presently available data and accounting for the differences in drugs of choice, carrier types, animal models, intervention strategies and outcome parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.